Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yee, Jeong | - |
dc.contributor.author | Kim, Woorim | - |
dc.contributor.author | Chang, Byung Chul | - |
dc.contributor.author | Chung, Jee Eun | - |
dc.contributor.author | Lee, Kyung Eun | - |
dc.contributor.author | Gwak, Hye Sun | - |
dc.date.accessioned | 2021-06-22T10:02:24Z | - |
dc.date.available | 2021-06-22T10:02:24Z | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1462-2416 | - |
dc.identifier.issn | 1744-8042 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/2901 | - |
dc.description.abstract | Aim: This study was designed to identify the possible effects of VEGFA polymorphisms on the occurrence of bleeding complications in patients with mechanical heart valves who have achieved therapeutic international normalized ratio (INR). Materials & methods: 13 SNPs of VEGFA were analyzed. Uni- and multi-variate analyses were conducted to identify associations between polymorphisms and bleeding complications. Results & conclusion: Patients with the CC genotype of rs35410204 had an approximately tenfold higher bleeding complication than those with the T allele. For rs866236, patients who had wild-type homozygotes showed an approximately 2.9-fold higher bleeding complication than C allele carriers. This study demonstrated that bleeding complications during warfarin therapy are associated with VEGFA polymorphisms in patients with mechanical heart valves. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.2217/pgs-2019-0005 | - |
dc.identifier.scopusid | 2-s2.0-85068130730 | - |
dc.identifier.wosid | 000478834800005 | - |
dc.identifier.bibliographicCitation | PHARMACOGENOMICS, v.20, no.9, pp 659 - 667 | - |
dc.citation.title | PHARMACOGENOMICS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 659 | - |
dc.citation.endPage | 667 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | VASCULAR MALFORMATIONS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | OUTPATIENTS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | PLASMA | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordAuthor | bleeding | - |
dc.subject.keywordAuthor | mechanical heart valve | - |
dc.subject.keywordAuthor | therapeutic INR | - |
dc.subject.keywordAuthor | VEGFA | - |
dc.subject.keywordAuthor | warfarin | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/pgs-2019-0005 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.